Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

Abstract

The good response to HU treatment that a significant number of southwest Iranian patients with beta-thalassemia patients had seems to correlate with particular haplotypes. This indicates that HU treatment is a sensible option for transfusion-dependent beta-thalassemia patients with a favorable molecular background.